Ahead of the March 6, 2026 FDA decision on Bristol Myers Squibb's Sotyktu (deucravacitinib) for psoriatic arthritis, a survey of 104 U.S. rheumatologists shows strong pre-launch awareness with one-third viewing it as a substantial advance. However, BMS ranks lowest among major pharmaceutical partners in rheumatology and is expected to capture roughly one-fifth of PsA patients through brand-to-brand share shifts rather than market expansion. The launch represents a critical opportunity for BMS to strengthen its standing in the specialty.

While investor attention remains focused on AI mega-caps and high-growth tech stocks, several large-cap companies are quietly delivering strong performance in 2026. Caterpillar, Oracle, AbbVie, and Progressive are highlighted as steady, profitable performers with consistent earnings and strong balance sheets that offer superior risk-adjusted returns without the hype.

The global Advanced Drug Delivery Systems market is projected to grow from $299.6 billion in 2025 to $487.4 billion by 2030 at a CAGR of 10.2%. Growth is driven by increasing chronic disease prevalence, nanotechnology advances, and R&D investments. Oncology leads adoption, with North America dominating market share while Asia-Pacific shows the fastest growth. Key innovations include strategic partnerships in antibody-drug conjugates and AI-powered drug development optimization.

The global ophthalmic drugs market is projected to reach US$41.88 billion in 2026 and grow at 7.9% CAGR through 2036, driven by biologic innovation, anti-VEGF therapies, AI-enabled diagnostics, and long-acting drug delivery systems. Key developments include expanded digital distribution channels and sustained-release implants reducing treatment burden for retinal disorders.

The FDA approved AbbVie and AstraZeneca's combination treatment (Venclexta and Calquence) for chronic lymphocytic leukemia (CLL), the first all-oral, fixed-duration option for previously untreated patients. The AMPLIFY Phase 3 trial showed 77% of patients were progression-free at three years versus 67% with standard chemotherapy, with a 35% reduced risk of disease progression or death.

AbbVie Inc. announced a quarterly cash dividend of $1.73 per share, payable May 15, 2026, to shareholders of record as of April 15, 2026. The company has increased its dividend by over 330% since its inception in 2013 and is a member of the S&P Dividend Aristocrats Index.

The global Alzheimer's Therapeutics Market is projected to surpass $6.0 billion in 2026, driven by rising disease prevalence and demand for disease-modifying therapies. Real-world evidence from lecanemab treatment shows strong patient continuation rates, supporting longer treatment durations. Market growth is fueled by increasing R&D investments and M&A activity, though challenges include skilled professional shortages and geopolitical risks from trade tariffs.

The global uterine fibroid market is projected to grow from USD 5.26 billion in 2025 to USD 9.43 billion by 2033 at a CAGR of 7.63%. Growth is driven by rising prevalence of fibroids (affecting 70-80% of women by age 50), technological advances in minimally invasive procedures with 60% adoption increase, and expanded healthcare infrastructure in emerging markets. Minimally invasive procedures and MRI-guided focused ultrasound are expected to see the fastest growth rates.

The global lip augmentation market is projected to grow from USD 7.91 billion in 2025 to USD 17.37 billion by 2035, with a CAGR of 8.21%. Growth is driven by increased social media influence on beauty trends, advancements in dermal filler technology, and broader acceptance of cosmetic procedures across age groups. Dermal fillers dominate the market with 69.69% share, while hyaluronic acid leads the filler type segment at 74.55% share.

AbbVie's stock price fell following its Q4 earnings report despite solid results, with revenue up 10% YoY to $16.6B. The market's concern centers on declining Humira sales post-patent expiration, though the company's growth drivers Skyrizi and Rinvoq are performing strongly and expected to generate combined sales above $31B. With 54 consecutive years of dividend increases and a robust pipeline including potential Parkinson's treatment, AbbVie remains an attractive income stock for long-term investors.

With 74% of institutional money managers expecting a market correction in 2026, the article recommends two defensive healthcare stocks—AbbVie and Merck—that historically perform well during downturns. Both companies offer robust dividends with yields around 2.7-3.1%, have raised dividends for 13+ consecutive years, and are projected to deliver strong growth in 2026.

The global Hepatitis B treatment market is valued at USD 4.52 billion in 2025 and is projected to reach USD 7.74 billion by 2033, growing at a CAGR of 6.97%. Growth is driven by expanded screening programs, increased antiviral therapy adoption, and novel treatment innovations. The U.S. market is expected to grow from USD 1.00 billion to USD 1.54 billion by 2033.